Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 13/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.38 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3841761 | 0.82 | CRHR1 (0.42) | CRHR1HSD11B1 | |
| SCHEMBL3364854 | 0.81 | CRHR1 (0.56) | CRHR1HSD11B1F2RL3 | |
| SCHEMBL13617783 | 0.81 | CRHR1 (0.41) | CRHR1F2RL3 | |
| SCHEMBL13617365 | 0.81 | CRHR1 (0.41) | CRHR1HSD11B1 | |
| SCHEMBL3364275 | 0.80 | CRHR1 (0.58) | CRHR1HSD11B1F2RL3 | |
| SCHEMBL3367536 | 0.80 | CRHR1 (0.49) | CRHR1HSD11B1F2RL3 | |
| SCHEMBL3843571 | 0.80 | CRHR1 (0.42) | CRHR1HSD11B1F2RL3 | |
| SCHEMBL3399007 | 0.79 | CRHR1 (0.53) | CRHR1HSD11B1F2RL3 | |
| SCHEMBL368235 | 0.79 | CRHR1 (0.53) | CRHR1HSD11B1F2RL3 | |
| SCHEMBL3367923 | 0.79 | CRHR1 (0.53) | CRHR1HSD11B1F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656353-B1 | GABANERGIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-7365211-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1656353-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050101614-A1 | For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain | ROCHE PALO ALTO LLC | 2005-05-12 | — | — | US | disclosed |
| WO-2005016892-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101614-A1 | For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain | HTR2C, GABRA2, GABRA4 | CRHR1 183/4885HSD11B1 479/4885F2RL3 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.